Botox

7 results

Allergan’s agreed price for Zeltiq Aesthetics’ shares represents a premium of 14.4 per cent on the company’s Friday close.

Botox maker Allergan said it would buy body-contouring product maker Zeltiq Aesthetics for about $2.48 billion (€2.34 billion), adding muscle to its l(...)

Stock exchange in Frankfurt, Germany: The Stoxx Europe 600 Index added 0.8 per cent, paring an earlier rise of as much as 1.4 per cent. Photograph:  Staff/Remote/Reuters

European shares rebounded further yesterday as investors speculated a sell-off that spurred their worst week since February was overdone, and banks a(...)

Botox is one of a number of pharmaceutical products made in Allergan’s Westport plant. Photograph: Shannon Stapleton/Files/Reuters

Allergan, the maker of Botox, has agreed to sell itself in a $66 billion (€53 billion) deal with fellow drugs group Actavis, with rival Valeant bowing(...)

Billionaire investor William Ackman. Photograph: Scott Eells/Bloomberg

A few months ago an innovative partnership between Valeant Pharmaceuticals and billionaire investor William Ackman to buy Botox maker Allergan look(...)

Founded in 1986 in Britain, Shire conducts most of its business in the United States and has been domiciled in Ireland for tax purposes since 2008. Photograph: JB Reed/Bloomberg News

US drugmaker AbbVie Inc has confirmed today that it had made a bid approach to Shire , which was rejected by the British group’s board. It said talks (...)

Valeant Pharmaceuticals  offered to buy Allergan, maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion in the latest step of the Canadian company’s plan to become one of the world’s largest drugmakers. Photographer: Patrick T. Fallon/Bloomberg

Valeant Pharmaceuticals said it began an exchange offer for Botox maker Allergan, taking its hostile $50.8 billion bid directly to shareholders. Que(...)

Joe Jimenez: refocusing Novartis on pharmaceuticals, eyecare and generics

A near $50 billion (€36 billion) takeover battle for the maker of Botox and a multibillion-dollar asset swap between Novartis and Glaxo-SmithKline (...)